Tibolone(Liviella)(Livial)
Suppliers
Names
[ CAS No. ]:
5630-53-5
[ Name ]:
Tibolone(Liviella)(Livial)
[Synonym ]:
EINECS 227-069-1
17-Hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one
Tibolone
7a-Methyl-5,10-norethindrone
7a-Methyl-17a-ethynyl-17b-hydroxy-19-norandrost-5(10)-en-3-one
LIVIELLA
19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7α,17α)-
Org OD 14
(7α,17α)-17-Hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one
7a-Methyl-D5,10-norethindrone
(7R,8R,9S,13S,14S,17R)-17-Ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
Estr-5(10)-en-3-one, 17-ethynyl-17-hydroxy-7-methyl-, (7α,17β)-
Livial
7a-Methyl-17a-ethynyl-17b-hydroxyestr-5(10)-en-3-one
MFCD00864178
(7a,17a)-17-Hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one
Chemical & Physical Properties
[ Density]:
1.1±0.1 g/cm3
[ Boiling Point ]:
447.4±45.0 °C at 760 mmHg
[ Melting Point ]:
169 °C
[ Molecular Formula ]:
C21H28O2
[ Molecular Weight ]:
312.446
[ Flash Point ]:
190.6±21.3 °C
[ Exact Mass ]:
312.208923
[ PSA ]:
37.30000
[ LogP ]:
4.03
[ Vapour Pressure ]:
0.0±2.5 mmHg at 25°C
[ Index of Refraction ]:
1.570
[ Storage condition ]:
2-8°C
MSDS
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H319
[ Precautionary Statements ]:
P305 + P351 + P338
[ Hazard Codes ]:
N
[ Risk Phrases ]:
R51/53
[ Safety Phrases ]:
S22-S24/25-S61
[ RIDADR ]:
UN 3077 9/PG 3
[ RTECS ]:
RC8964020
Precursor & DownStream
Precursor
DownStream
Articles
Neurochem. Res. 39(9) , 1776-86, (2014)
Oxidative stress is related to the development of central nervous system diseases involving memory processes. Cholinergic system and memory processes are disrupted by ozone exposure. In rats, ozone in...
Clin. Endocrinol. (Oxf.) 78(2) , 297-302, (2013)
To determine the effects of tibolone or oestradiol (E(2) )/norethisterone acetate (NETA) hormone replacement therapy on glucose and insulin metabolism in postmenopausal women.Single-centre double-blin...
Maturitas 74(2) , 172-8, (2013)
This study compared the effects of a continuous-combined regimen of low-dose hormone therapy (LD-HT) versus tibolone and supplemental calcium/vitamin D3 (control) on quality of life (QoL) in symptomat...